|
Notes Payable (Narrative) (Details) (USD $)
|
3 Months Ended | 9 Months Ended | 1 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
General Electric Capital Corporation [Member]
|
Jun. 30, 2013
General Electric Capital Corporation [Member]
installment
|
Jun. 25, 2013
General Electric Capital Corporation [Member]
|
Sep. 30, 2012
Hercules Technology II, L.P. Notes [Member]
|
Jun. 24, 2013
Hercules Technology II, L.P. Notes [Member]
|
Jun. 25, 2013
Hercules Technology II, L.P. Notes [Member]
|
Sep. 30, 2012
Hercules Technology II, L.P. Notes [Member]
|
Sep. 30, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
|
Jun. 25, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
|
Sep. 30, 2013
Series X Warrants and Series AA Warrants [Member]
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
|
Jun. 30, 2013
Series X Warrants and Series AA Warrants [Member]
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
|
Jun. 30, 2013
Series HH Warrants [Member]
|
Jun. 30, 2013
Series HH Warrants [Member]
General Electric Capital Corporation [Member]
|
Jun. 25, 2013
Series HH Warrants [Member]
General Electric Capital Corporation [Member]
|
Jun. 30, 2013
Preferred Stock [Member]
|
Sep. 30, 2013
Preferred Stock [Member]
|
Jun. 30, 2013
Common Stock [Member]
|
Sep. 30, 2013
Common Stock [Member]
|
Sep. 30, 2013
Maximum [Member]
|
Sep. 30, 2013
Maximum [Member]
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
|
|
| Debt Instrument [Line Items] | ||||||||||||||||||||||||
| Debt Instrument, Face Amount | $ 25,000,000 | |||||||||||||||||||||||
| Debt instrument, interest rate | 9.83% | 10.00% | ||||||||||||||||||||||
| Number of shares underlying warrant issued | 301,205 | 301,205 | ||||||||||||||||||||||
| Exercise price of warrant issued | 2.49 | 2.49 | 3.83 | |||||||||||||||||||||
| Number of installment payments on notes payable | 30 | |||||||||||||||||||||||
| Percentage of original principal amount of loan to be paid as a fee | 4.00% | |||||||||||||||||||||||
| Debt Instrument, Covenant Description | 17,600,000 | |||||||||||||||||||||||
| Notes Payable | 25,000,000 | 3,200,000 | ||||||||||||||||||||||
| Unamortized debt discount | 1,800,000 | 1,900,000 | 187,000 | |||||||||||||||||||||
| Debt issuance cost | 783,000 | 881,000 | ||||||||||||||||||||||
| Principal payments on notes payable | 5,982,156 | 620,480 | 620,000 | 1,300,000 | 4,400,000 | 620,000 | 4,781,333 | |||||||||||||||||
| Debt instrument, end of term fee | 250,000 | |||||||||||||||||||||||
| Debt instrument, early payment penalty | 66,000 | |||||||||||||||||||||||
| Loss on extinguishment of debt | 0 | 0 | (1,372,266) | 0 | 429,000 | |||||||||||||||||||
| Unamortized debt issuance cost | 176,000 | |||||||||||||||||||||||
| Line of Credit Facility, Maximum Borrowing Capacity | 35,000,000 | |||||||||||||||||||||||
| Interest rate in addition to Prime rate | 6.75% | |||||||||||||||||||||||
| Interest rate in addition to amended agreement | 0.125% | |||||||||||||||||||||||
| Percentage of VWAP for conversion calculation | 90.00% | |||||||||||||||||||||||
| Number of days preceding the date of conversion request | 10 days | |||||||||||||||||||||||
| Minimum revenue from sales and licensing for mandatory repayment due | 2,000,000 | |||||||||||||||||||||||
| Long-term embedded liability, estimated fair value | 943,000 | |||||||||||||||||||||||
| Derivative, Gain (Loss) on Derivative, Net | (388,000) | |||||||||||||||||||||||
| Series B preferred stock issued, shares | 2,364.9 | 2,364.9 | ||||||||||||||||||||||
| Number of common shares underlying Series B Preferred Stock | 7,733,223 | 7,733,223 | ||||||||||||||||||||||
| Shares conversion, number of common stock equivalent to each preferred stock | 3,270 | 3,270 | ||||||||||||||||||||||
| Long-term Debt, Fair Value | 4,600,000 | |||||||||||||||||||||||
| Debt Instrument, Unused Borrowing Capacity, Amount | 31,800,000 | |||||||||||||||||||||||
| Interest expense related to debt | $ 258,000 | $ 147,000 | $ 502,000 | $ 407,000 | ||||||||||||||||||||